ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1434

The Longitudinal Association Between Inflammation and Blood Pressure in Rheumatoid Arthritis

Chih-Chin Liu1, Daniel H. Solomon2, Rishi Desai3, Seoyoung C. Kim4 and Katherine Liao5, 1Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3PharmacoEpidemiology & PharmacoEconomics, Brigham and Women's Hospital, Boston, MA, 4Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 5Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: hypertension, inflammation and rheumatoid arthritis, pathogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

Background/Purpose

Inflammation is hypothesized to have direct effects on arterial endothelial and vasomotor function, functions which regulate blood pressure (BP).  While inflammation has been implicated in the development of elevated BP, few studies have examined BP longitudinally after diagnosis of an inflammatory disease.  The objective of this study is to examine the longitudinal association between changes in levels of inflammation and changes in BP in patients with rheumatoid arthritis (RA).

Methods

We studied RA subjects classified using a validated electronic medical record (EMR) algorithm (positive predictive value 94%) linked with Medicare Claims Data (patients age>65 years) between 2006-2010.  We extracted EMR data on age, gender, systolic BP (SBP), diastolic BP (DBP), erythrocyte sedimentation rates (ESR), smoking status (ever/never), and calendar year of measurements.  We extracted RA treatment data from Medicare prescription data including non-steroidal anti-inflammatory drugs (NSAIDs), anti-hypertensive drugs and dates of claims.  We studied all subjects with ≥2 concurrent BP and ESR measurements at separate visits at least one week apart.  The baseline was defined as the 1st concurrent ESR and BP measurement 6 months after the 1st Medicare claims date.  We examined the association between the change in ESR and change in SBP between baseline and follow-up using multiple linear regression models adjusted by age, gender and smoking status.  We performed sensitivity analyses by including potential treatments received +/- 15 days of ESR measurements that may affect blood pressure individually into the models; the treatments included anti-TNF, NSAIDs, anti-hypertensive medications, and steroids.

Results

We identified 313 subjects with ≥2 instances with ESR and BP measured on the same date.  The mean age was 69.2 years (SD 10.3), 83.7% female, and 57.6% ACPA positive.  The mean SBP was 134.4(SD 18.8) mm/Hg, mean DBP was 75.7(SD 12) mm/Hg, and the mean ESR was 32 (SD 27.1) mm/hour.  We observed an inverse association between change in ESR and SBP, where every 10mm/hour increase in ESR was associated with a 1.2mm/Hg lower in SBP, adjusted by age, gender and smoking status (Table).  A similar relationship was found with DBP: each 10mm/hour increase in ESR was associated with a 0.43 mm/Hg lower DBP (95% CI -0.75, -0.01, p=0.009).  The effect size of the association between change in ESR and change in BP was similar with the addition of indicator variables for anti-hypertensive treatments, anti-TNF, and NSAIDs into the model.   

Conclusion

In a linked dataset containing clinical data from the EMR and detailed prescription data from Medicare, we observed that increases in ESR were associated with a modest reduction in blood pressure.  These findings have potential implications for CV risk assessment in RA patients who commonly experience large fluctuations in inflammation.

 

Table.  The association between change in ESR (per 10mm/hour) increase with change in systolic blood pressure (SBP), N=313.

 

Linear regression models for DESR and DSBP, adjusted by:

DSBP (mm/Hg) per 10mm/h D ESR

95% CI

Model 1: Age, gender, race, smoking

-1.22

-1.74, -0.71

 

Sensitivity analyses

 

 

Model 2: Model 1 + anti-hypertensive

-1.21

-1.72, -0.70

Model 2+ anti-TNF

-1.19

-1.70, -0.70

Model 2+ NSAIDs

-1.21

-1.72, -0.70

Model 2+ Steroids

-1.21

-1.72, -0.70

Model 3: Model 1 + anti-hypertensive +

anti-TNF + NSAIDs + steroids

-1.16

-1.67, -0.65

*All p-values <0.0001

 


Disclosure:

C. C. Liu,
None;

D. H. Solomon,
None;

R. Desai,

Biogen Idec,

1;

S. C. Kim,

Pfizer Inc,

2;

K. Liao,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-longitudinal-association-between-inflammation-and-blood-pressure-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology